HomeDealsNegotiationsPolicyPipelineMoneyPeopleDataThe WeekPharmTech 100Deal TrackerResearch
Deals

Boehringer Ingelheim and Zai Lab team up for dual DLL3 therapy study

Boehringer Ingelheim and Zai Lab have entered into a clinical collaboration to investigate a dual DLL3-targeting approach for patients with ES-SCLC and other NECs.

By Pharmaceutical Technology · Apr 16, 2026 · via Pharmaceutical Technology
Boehringer Ingelheim and Zai Lab team up for dual DLL3 therapy study

Image: Pharmaceutical Technology

This is an aggregated industry headline. Read the full story at Pharmaceutical Technology →

Tags
theweekformat:headlineheadlinePharmaceutical Technology
The Insider - Weekly pharma intelligence
Deals, negotiations, and policy analysis. Delivered when it matters.
No sponsored content. No noise. Unsubscribe anytime.
More from Deals
All Deals →
Lilly Spends Up to $3.8B on Three Vaccine Developers
DealsBriefing
Lilly Spends Up to $3.8B on Three Vaccine Developers
The pharma giant’s latest acquisitions of Curevo, LimmaTech, and Vaccine Company reinforce its pivot from trea…
May 26, 2026
Medtronic inks $650M deal for SPR Therapeutics
DealsFierceBiotech ↗
Medtronic inks $650M deal for SPR Therapeutics
Medtronic has entered a deal to acquire SPR Therapeutics, a Cleveland-based company whose flagship product del…
May 24, 2026
CVC consortium tables $12.4bn bid to delist Italian drugmaker Recordati
DealsPharmaceutical Technology ↗
CVC consortium tables $12.4bn bid to delist Italian drugmaker Recordati
The tender offer is for €51.29 per share, representing a 13% premium on Recordati’s share price before the tak…
May 22, 2026